Suppr超能文献

人血小板中纤溶酶原激活物抑制剂的检测及部分特性分析

Detection and partial characterization of an inhibitor of plasminogen activator in human platelets.

作者信息

Erickson L A, Ginsberg M H, Loskutoff D J

出版信息

J Clin Invest. 1984 Oct;74(4):1465-72. doi: 10.1172/JCI111559.

Abstract

In this study, we demonstrate the presence of a previously undescribed fibrinolytic inhibitor in human serum. It has an apparent molecular weight of 50,000 and is not detected in serum derived from platelet-poor plasma, suggesting that it originates from platelets. This conclusion is supported by a number of observations. For example, extracts of washed, gel-filtered human platelets contain an inhibitor of similar activity and size, and physiological concentrations of thrombin induce its release from the platelets. Moreover, the kinetics and dose dependency of this release are similar to those observed for the release of platelet factor 4, and the release of both molecules is blocked by pretreating the platelets with prostaglandin E1 and theophylline. Mixing experiments, which were devised to investigate the specificity of the inhibitor, showed that the fibrinolytic activity initiated by both urokinase and tissue-type plasminogen activator was blocked by platelet releasate in a dose-dependent manner. In both cases, the amount of inhibition increased when the releasates were preincubated with the purified activators, indicating a direct interaction between the activators and an inhibitor(s). The inhibitory activity was removed by preincubating the releasates with antiserum prepared against an antiactivator purified from cultured bovine aortic endothelial cells. These results indicate that platelets contain an inhibitor which is released by thrombin, inhibits both urokinase and tissue-type plasminogen activator, and is immunologically similar to an inhibitor produced by endothelial cells. This molecule may represent a new class of inhibitors, the antiactivators, which function together with alpha 2-antiplasmin to regulate the fibrinolytic system of the blood. Its release from platelets by thrombin may protect the growing thrombus against premature dissolution initiated by plasminogen activators released by the endothelium.

摘要

在本研究中,我们证明了人血清中存在一种先前未被描述的纤维蛋白溶解抑制剂。其表观分子量为50,000,在缺乏血小板的血浆衍生的血清中未检测到,这表明它起源于血小板。这一结论得到了多项观察结果的支持。例如,洗涤过的、经凝胶过滤的人血小板提取物含有一种活性和大小相似的抑制剂,凝血酶的生理浓度可诱导其从血小板中释放。此外,这种释放的动力学和剂量依赖性与血小板因子4释放时观察到的相似,并且通过用前列腺素E1和茶碱预处理血小板可阻断这两种分子的释放。为研究该抑制剂的特异性而设计的混合实验表明,尿激酶和组织型纤溶酶原激活剂引发的纤维蛋白溶解活性被血小板释放物以剂量依赖性方式阻断。在这两种情况下,当释放物与纯化的激活剂预孵育时,抑制量增加,表明激活剂与一种或多种抑制剂之间存在直接相互作用。通过将释放物与针对从培养的牛主动脉内皮细胞纯化的抗激活剂制备的抗血清预孵育,可去除抑制活性。这些结果表明,血小板含有一种由凝血酶释放的抑制剂,它抑制尿激酶和组织型纤溶酶原激活剂,并且在免疫学上与内皮细胞产生的一种抑制剂相似。这种分子可能代表一类新的抑制剂,即抗激活剂,它与α2-抗纤溶酶共同作用来调节血液的纤维蛋白溶解系统。凝血酶使其从血小板中释放可能保护正在形成的血栓免受内皮细胞释放的纤溶酶原激活剂引发的过早溶解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/226b/425316/8ec078578efd/jcinvest00136-0347-a.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验